Temozolomide-associated organizing pneumonitis

Mayo Clinic Proceedings

Volumn 82, Issue 6, 2007, Pages 771-773

  Maldonado, Fabien ^a   Limper, Andrew H ^a   Lim, Kaiser G ^a   Aubry, Marie Christine ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ATENOLOL; COTRIMOXAZOLE; DEXAMETHASONE; HYDROCHLOROTHIAZIDE; LEVOFLOXACIN; LEVOTHYROXINE; NIFEDIPINE; PREDNISONE; SIMVASTATIN; TEMOZOLOMIDE;

AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHILL; COUGHING; DRUG EFFECT; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEVER; GLIOBLASTOMA; HEMOPTYSIS; HUMAN; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; ORGANIZING PNEUMONIA; RARE DISEASE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 34249930493     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.6.771     Document Type: Article

References (10)

1. Brandes AA, Tosoni A, Amista P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? a phase II trial. Neurology. 2004; 63:1281-1284.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352: 987-996.
3. Limper AH. Chemotherapy-induced lung disease. Clin Chest Med. 2004; 25:53-64.
4. Gérard B, Aamdal S, Lee SM, et al. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine - in patients with melanoma. Eur J Cancer. 1993;29A:711-719.
5. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer. 2006 Nov 6;95:1155-1160. Epub 2006 Oct 3.
6. Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG, Cancer and Leukemia Group B. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer. 2006;107:1883-1890.
7. Chang SM, Seiferheld W, Curran W, et al. Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. Int J Radiat Oncol Biol Phys. 2004;59:1122-1126.
8. Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol. 2006;24:4412-4417.
9. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications [published correction appears in J Clin Oncol. 2004;22:2038]. J Clin Oncol. 2004 Feb 15;22:610-616. Epub 2004 Jan 15.
10. Cordier JF. Cryptogenic organizing pneumonia. Clin Chest Med. 2004; 25:727-738.